RETROSPECTIVE AUDIT OF PATIENTS TREATED FOR MDR-TB IN RE-TREATMENT CATEGORY
Abstract
Objective: To determine the efficacy of our modified anti-tuberculosis regimen in adult patients withmulti-drug-resistant tuberculosis (MDR-TB) in the re-treatment category. Methods: Retrospective chartreview of 176 patients in re-treatment category with diagnosis of MDR-TB from 1st Jan 1993 to 31st Dec2002 managed at the Department of Pulmonology Military Hospital Rawalpindi, Pakistan. All the patientswere given four standard first line anti-TB drugs along with any two second line drugs out ofOfloxacin/Ciprofloxacin/Levofloxacin, Amikacin, or Clarithromycin and treatment was modified afteravailability of drug susceptibility testing (DST). Results: Seventy-two percent of the patients were youngmen with mean age of 32.28±8.7 yrs, 53.4% had moderately advanced while nearly 30% had extensivedisease. One-third cases had contact with a patient of pulmonary tuberculosis out of which one fifth hadcontact with a MDR-TB patient. Mean duration of diagnosis of tuberculosis before therapy was41.11±14.32 months and 70% of the cases had received at least 2 prior anti-TB regimens. They hadreceived a median of four anti-TB drugs in past and were infected with organisms that were resistant to amedian of 3 first line anti-TB drugs. Resistance to Ethambutol and PZA was about 18% and 11%respectively. A median of six anti-TB drugs was used while mean duration of therapy was 22.17±2.17months. Bacteriological cure was achieved in about 90% cases while radiological response wasdocumented in nearly 78%. Conclusion: Modified initial management strategy followed by DST guidedtherapy has yielded excellent results and needs to be assessed in further trials for wider application.Keywords: Modified regimen, Re-treatment TB, Multi-drug-resistant tuberculosis, MDR-TB, TuberculosisReferences
Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C.
Tuberculosis. Lancet 2003;362:887–99.
Schluger NW, Harkin TJ, Rom WN. Principles of therapy of
tuberculosis in the modern era. In: Rom WN & Garay S,
(Eds) Tuberculosis, 1st edn New York: Little Brown and
Company; 1996. p.751–61.
Narita M, Alonso P, Lauzardo M, Hollender ES, Pitchenik
AE, Ashkin D. Treatment experience of Multi Drug
Resistance Tuberculosis in Florida, 1994-1997. Chest
;120:343–8.
Espinal MA. The global situation of MDR-TB. Tuberculosis
;83:44–51.
Bastain I, Colebunders R. Treatment and prevention of
multidrug resistant tuberculosis. Drugs1999;58(4):633–41.
World Health Organization. Anti-tuberculosis drug resistance
in the world. The WHO/IUATLD Global Project on AntiTuberculosis Drug Resistance Surveillance
(WHO/TB/97.229). Geneva, World Health Organization
Document, 1997.
World Health Organization. Anti-tuberculosis drug resistance
in the world. Third global report. The WHO/IUATLD Global
Project on Anti-Tuberculosis Drug Resistance Surveillance
(WHO/CDC/TB/2004). Geneva, World Health Organization
document, 2004.
Espinal MA, Kim SJ, Suárez PG, Kam KM, Khomenko AG,
Migliori GB, et al. Standard short-course chemotherapy for
drug-resistant tuberculosis: treatment outcomes in 6
countries. JAMA 2000;283:2537–45.
Kimerling ME, Kluge H, Vezhnina N, Iacovazzi
T, Demeulenaere T, Portaels F, et al. Inadequacy of the
current WHO re-treatment regimen in a central Siberian
prison: treatment failure and MDR-TB. Int J Tuberc Lung
Dis 1999;3:451–3.
Butt T, Ahmad R N, Kazmi S Y, Rafi N. Multi-drug resistant
Tuberculosis in Northern Pakistan. J Pak Med Assoc
;54:469–72.
Almani SA, Memon NM, Qureshi AF. Drug Resistant
Tuberculosis in Sindh. J Coll Physicians Surg Pak
;12(3):136–9.
Iseman MD. Mycobacterial Diseases of the Lungs. In:
Hanley ME, Welsh CH (Eds). Current Diagnosis &
Treatment in Pulmonary Medicine. New York: Lange
Medical Books/MaGraw Hill; 2003. p. 399–413.
Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L,
Horsburgh CR. Treatment of 171 patients with pulmonary
tuberculosis resistant to isoniazid and rifampin. N Engl J
Med 1993;328:527–32.
Chan ED, Laurel V, Strand MJ, Chan JF, Huynh MLN,
Goble M, et al. Treatment and Outcome Analysis of 205
Patients with Multidrug-resistant Tuberculosis. Am J Respir
Crit Care Med 2004;169:1103–9
Mitnick C, Bayona J, Palacios E, Shin S, Furin J, Alcantara
F, et al. Community Based Therapy for Multi Drug Resistant
Tuberculosis in Lima, Peru. N Engl J Med 2003;348:119–28.
Suo J, Yu MC, Lee CN, Chiang CY, Lin TP. Treatment of
multi-drug resistant tuberculosis in Taiwan. Chemotherapy
;42(Suppl)3:20–3.
Park, SK, Kim CT, Song SD. Outcome of chemotherapy in
patients with pulmonary tuberculosis resistant to isoniazid
and rifampin. Int J Tuberc Lung Dis 1998;2:877–84.
Tahaoglu K, Torun T, Sevin T, Atac G, Kir A, Karasulu L,
Ozmen I, et al. The Treatment of Multidrug-Resistant
Tuberculosis in Turkey. N Engl J Med 2001;345:170–4.
Kim SJ. Drug susceptibility testing in tuberculosis: methods
and reliability of the results. Eur Respir J 2005;25:564–9.
Caminero JA. Management of multidrug-resistant
tuberculosis and patients in re-treatment. Eur Respir J
;25:928–36.
Ormerod LP. Multidrug resistant tuberculosis (MDR-TB):
epidemiology, prevention and treatment. Br Med Bull
;73–74:17–24.
Partners in Health Program in Infectious Disease and Social
Change, Harvard Medical School. The PIH Guide to the
Medical Management of Multi-Drug Resistant Tuberculosis.
Boston, MA. Partners in Health, 2003.
Pierri GD, Bonora S. Which agents should we use for the
treatment of multi-drug resistant Mycobacterium
tuberculosis? J Antimicrob Chemother 2004; 54:593–602.